These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30797699)

  • 1. Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma.
    Dean MK; Studenski MT; Paez-Escamilla MA; Walter SD; Kwon D; Markoe AM; Harbour JW; Samuels SE
    Brachytherapy; 2019; 18(3):404-410. PubMed ID: 30797699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric benefit of a new ophthalmic radiation plaque.
    Marwaha G; Wilkinson A; Bena J; Macklis R; Singh AD
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1226-30. PubMed ID: 22658440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
    Lee YC; Lin SC; Kim Y
    Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review.
    Le BHA; Kim JW; Deng H; Rayess N; Jennelle RL; Zhou SY; Astrahan MA; Berry JL
    Brachytherapy; 2018; 17(6):981-989. PubMed ID: 30082188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
    Puusaari I; Heikkonen J; Kivelä T
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EyeDose: An open-source tool for using published Monte Carlo results to estimate the radiation dose delivered to the tumor and critical ocular structures for
    Deufel CL; McCauley Cutsinger S; Corbin KS; Dalvin LA; Petersen IA
    Brachytherapy; 2021; 20(1):189-199. PubMed ID: 33187821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
    Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
    Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of dose to the macula, optic disc, and lens in relation to vision toxicities - A retrospective study using COMS eye plaques.
    Oare C; Sun S; Dusenbery K; Reynolds M; Koozekanani D; Gerbi B; Ferreira C
    Phys Med; 2022 Sep; 101():71-78. PubMed ID: 35981450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric and radiobiologic comparison of
    Gorovets D; Gagne NL; Melhus CS
    Brachytherapy; 2017; 16(2):433-443. PubMed ID: 28161431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optic disc dose reduction in ocular brachytherapy using
    Lee YC; Lin SC; Kim Y
    J Appl Clin Med Phys; 2020 Sep; 21(9):57-70. PubMed ID: 32656945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of tumor shape and location in eye plaque brachytherapy dosimetry.
    Studenski MT; Patel NV; Markoe A; Harbour JW; Samuels SE
    Brachytherapy; 2020; 19(2):249-254. PubMed ID: 32061535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying the dosimetric influences of radiation coverage and brachytherapy implant placement uncertainty on eye plaque size selection.
    Gagne NL; Rivard MJ
    Brachytherapy; 2013; 12(5):508-20. PubMed ID: 23466357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental validation of a new COMS-like 24 mm eye plaque for the treatment of large ocular melanoma tumors.
    McCauley Cutsinger S; Forsman R; Corner S; Deufel CL
    Brachytherapy; 2019; 18(6):890-897. PubMed ID: 31444131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
    Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
    Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism.
    Deufel CL; Furutani KM
    Brachytherapy; 2015; 14(2):209-30. PubMed ID: 25533415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.
    Morrison H; Menon G; Larocque MP; Jans HS; Weis E; Sloboda RS
    Med Phys; 2016 Aug; 43(8):4891. PubMed ID: 27487906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
    Gagne NL; Leonard KL; Rivard MJ
    Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas.
    Puusaari I; Heikkonen J; Summanen P; Tarkkanen A; Kivelä T
    Ophthalmology; 2003 Nov; 110(11):2223-34. PubMed ID: 14597534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
    Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
    Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control.
    Quivey JM; Augsburger J; Snelling L; Brady LW
    Cancer; 1996 Jun; 77(11):2356-62. PubMed ID: 8635107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.